News

Drug heals broken heart
Enlarge image

ResearchUK

Drug heals broken heart

28.05.2013 - Researchers have presented new preclinical data on a mitochondria-protecting drug that could reduce tissue damage following heart attacks.

During a heart attack, the major vessels that supply the heart with blood become blocked, preventing oxygen from reaching an area of the heart tissue. When the patient reaches hospital, doctors remove the blockage using medicines or surgery and restore blood flow to the heart, however in almost 100% of cases, tissue damage occurs when blood flow is restored. 

A team headed by Michael Murphy has now unravelled how the novel mitochondria-selective S-nitrosating agent, MitoSNO, protects the heart from oxidative damage, which occurs when blood flow is restored after infarction (Nature Medicine ). In a mouse model, they found that S-nitrosation of the mitochondrial complex I slows the reactivation of mitochondria during the crucial first minutes of the reperfusion of ischemic tissue, thereby decreasing ROS production, oxidative damage and tissue necrosis. 

MitoSNO works by briefly ‘switching off’ the mitochondria in the first few minutes after blood flow is returned to prevent a build-up of free radicals that can kill heart cells through apoptosis. To achieve this, MitoSNO is designed to accumulate inside heart mitochondria rapidly after its injection into the blood. In detail, MitoSNO1-induced production of nitric oxide radicals reversibly inhibits respiration at cytochrome c oxidase and increased extracellular oxygen concentration under hypoxic conditions. 

Dr Mike Murphy from the MRC Mitochondrial Biology Unit, who led the study, said: “When cells are starved of oxygen for any length of time, they begin to shut down. When blood rushes back, the mitochondria go into over-drive, churning out free radicals that cause the cells to die. MitoSNO effectively flicks a switch in the mitochondria, slowing down reactivation during those critical first minutes when blood flow returns and protecting the heart tissue from further damage. The researchers now hope to secure funding to test their new compound in early human studies.  

 © eurobiotechnews.eu/tg

BusinessSpainUKSweden

31.07.2014 Astrazeneca is buying the rights to Almirall’s respiratory drugs in a deal worth up to €1.56bn.

BusinessFranceGermanySwitzerlandUK

30.07.2014 Rumours have it that French Danone wants to sell its medical nutrition business to US drugmaker Hospira for US$5bn in yet another tax inversion deal.

RegulationUKEU

29.07.2014 The first vaccine for malaria may be within reach: The European Medicines Agency has accepted Glaxosmithkline’s malaria vaccine candidate RTS,S for regulatory review.

FundingEU

25.07.2014 The European Commission aims to support innovation in Europe and announced a "Fast Track to Innovation" pilot as well as five innovation prices under Horizon 2020.

ResearchUKEU

23.07.2014 In the largest genomic study published on any psychiatric disorder so far, researchers have indentified 83 new locations in the human genome associated with the risk of developing schizophrenia.

BusinessUKIreland

21.07.2014 Abbvie’s tenacious pursuit of British rival Shire is finally paying off: The two companies have unveiled their transatlantic merger worth £32bn (€40bn).

ResearchEUSwitzerland

17.07.2014 A trans-border, cross-disciplinary project that aims to model the human brain in a computer has drawn heavy criticism from scientists pledging to boycott the project.

MergerUK

16.07.2014 After rejecting three merger propositions from US competitor Abbvie, Shire has now given up resistance to the deal and is recommending a new and improved offer worth £31.3bn.

AcquisitionUKDenmarkSpainGermanyFrance

15.07.2014 British specialty pharma company Prostrakan is handing over £230m for Archimedes Pharma Limited, a company that brings its lead product Pecfent and its proprietary drug delivery technology platform into the deal.

FundingEU

11.07.2014 Among the seven newly launched Joint Technology Initiatives (JTI) of Horizon2020 are two with deep roots in biotech: IMI is going into its second round while the newly established Bio-based Industries partnership invests in bioeconomy.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • NOVACYT (F)4.97 EUR11.43%
  • PROSENSA (NL)10.24 USD5.89%
  • NEUROVIVE PHARMACEUTICAL AB (S)74.00 SEK5.71%

FLOP

  • ANTISOMA (UK)1.32 GBP-14.84%
  • XENETIC BIOSCIENCES (UK)6.00 GBP-14.29%
  • STENTYS (F)7.26 EUR-12.32%

TOP

  • WILEX (D)2.70 EUR229.3%
  • NEUROVIVE PHARMACEUTICAL AB (S)74.00 SEK52.6%
  • Allergy Therapeutics (UK)20.00 GBP34.4%

FLOP

  • HYBRIGENICS (F)1.68 EUR-29.7%
  • GW PHARMACEUTICALS (UK)418.50 GBP-20.1%
  • PHARMING (NL)0.44 EUR-20.0%

TOP

  • SANTHERA (CH)59.90 CHF2836.3%
  • GW PHARMACEUTICALS (UK)418.50 GBP634.2%
  • PAION (D)2.50 EUR284.6%

FLOP

  • EVOCUTIS (UK)0.21 GBP-92.7%
  • CYTOS (CH)0.27 CHF-92.0%
  • THROMBOGENICS (B)9.16 EUR-70.3%

No liability assumed, Date: 31.07.2014